Citation Tools
PDFClinical/translational cancer immunotherapy
Original research
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817